摘要
目的观察多瑞吉治疗鼻咽癌放化疗引起口腔黏膜炎所致疼痛的疗效。方法将45例经病理学诊断明确为鼻咽癌并在放疗或化疗过程中出现急性口腔黏膜炎所致中、重度疼痛患者,分为研究组23例和对照组22例,研究组在常规治疗的基础上加用多瑞吉,对照组仅行常规治疗,观察两组患者治疗过程中及治疗结束后的镇痛作用、生活质量评分和不良反应。结果研究组疼痛缓解有效率为82.61%,对照组为31.82%;研究组较对照组生活质量明显改善,差异有统计学意义;研究组不良反应发生率低,且均能耐受。结论多瑞吉用于鼻咽癌放化疗相关性口腔黏膜炎所致中、重度疼痛,镇痛作用强,不良反应轻,能够明显改善患者的生活质量,便于治疗的顺利完成。
Objective To study the curative effect of durogesic treatment on pain induced by superficial temporal artery intubation radiochemotherapy-related oral mucositis.Methods 45 patients with nasopharyngeal cancer confirmed by pathology and pain caused by acute oral mucositis during radiotherapy or chemotherapy were divided into treatment group (durogesic plus conventional treatment,23 cases) and the control group (conventional treatment,22 cases).Two groups were observed on the analgesic effects,quality of life scores and adverse reactions during and after radiochemotherapy.Results The pain relief rate in the treatment group and control group was 82.61%and 31.82%,respectively,showing the significant difference.The quality of life was improved significantly in the treatment group.Adverse reactions were mainly constipation,nausea,vomiting,dizziness and drowsiness.The incidence of adverse reactions in the treatment group was low and tolerable.There was no drug dependence after treatment.Conclusion Durogesic is effective with few adverse reactions in the treatment of pain induced by superficial temporal artery intubation radiochemotherapy-related oral mucositis.It can also improve the patients' life quality and ensure uneventful treatment with high clinical application value.
出处
《中国药业》
CAS
2010年第17期67-69,共3页
China Pharmaceuticals